HW
REGN icon

Hedeker Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Hedeker Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,862
Closed -$2.3M – 82
2021
Q1 		$2.3M Buy
4,862
+25
+0.5% +$12.2K 0.81% 46
2020
Q4 		$2.34M Buy
4,837
+497
+11% +$268K 0.82% 44
2020
Q3 		$2.43M Buy
4,340
+3,306
+320% +$2M 1.15% 41
2020
Q2 		$644K Buy
+1,034
New +$587K 0.33% 57

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Hedeker Wealth's REGN Position: Q2 2021 in Review

Hedeker Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 4,862 shares — an estimated $2.3M sold.

Hedeker Wealth first reported a position in REGN in Q2 2020 and held it in 4 quarters. The position peaked at $2.43M in Q3 2020. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

  • Hedeker Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hedeker Wealth sold 4,862 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $2.3M.
  • Hedeker Wealth first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Hedeker Wealth's Regeneron Pharmaceuticals position peaked at $2.43M in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Hedeker Wealth's 13F filing for Q2 2021, filed 21 Jul 2021.